Tot Biopharm Opens New Biologics Facility in Suzhou

Tot Biopharm, a Suzhou oncology company, completed a monoclonal antibodies (mAb) manufacturing facility. The 13,000 square meter site will have a capacity of 16,000L when it is completely built out. Tot will use the plant for its own portfolio of oncology drugs as well as offering CDMO services to other biopharmas. The facility will offer upstream R&D, pilot-scale production, clinical trial-scale drug manufacturing and commercial production. Tot said the plant will produce both biologic drugs and small molecular drugs at commercial scale. More details.... Share this with colleagues: // //